Abstract：Objective To study the correlation between 25-hydroxyvitamin D [25-(OH)D] and nephroblastoma in children and its value in assessing the prognosis of the disease. Methods A total of 50 children with nephroblastoma who were admitted from January 2018 to December 2022 were included as the nephroblastoma group, and according to the postoperative pathological type, they were divided into a good prognosis group with 38 children and a poor prognosis group with 12 children. A total of 50 healthy children who underwent physical examination during the same period of time served as the healthy control group. The above groups were compared in terms of serum creatinine and 25-(OH)D level. A Spearman correlation analysis was used to investigate the correlation between serum 25-(OH)D level and therapeutic effect reaction. A multivariate logistic regression analysis was used to identify the risk factors affecting the prognosis of nephroblastoma in children. Results The nephroblastoma group had significantly lower levels of serum creatinine and 25-(OH)D than the healthy control group (P<0.05). Compared with the good prognosis group, the poor prognosis group had a significantly larger tumor diameter, a significantly higher proportion of children with stage III-IV tumors, a significantly higher rate of tumor metastasis, and significantly lower serum levels of creatinine and 25-(OH)D (P<0.05). The Spearman correlation analysis showed that serum 25-(OH)D level was negatively correlated with therapeutic effect reaction (rs=-0.685, P<0.001). The multivariate logistic regression analysis showed that tumor diameter ≥10 cm, stage III-IV tumors, presence of tumor metastasis, and 25-(OH)D <19 ng/mL were closely associated with the poor prognosis of nephroblastoma in children (P<0.05). Serum 25-(OH)D level had an area under the curve of 0.805 (95%CI: 0.706-0.903, P<0.001) in evaluating the prognosis of nephroblastoma in children, with a Youden index of 0.512, a sensitivity of 0.938, and a specificity of 0.575 at the optimal cut-off value of 1.764 ng/mL. Conclusions There is a significant correlation between 25-(OH)D level and the prognosis of nephroblastoma in children, and 25-(OH)D can be used for prognosis prediction.
ZHAO Li,MA Xu-Kai,LIU Yu et al. Correlation between 25-hydroxyvitamin D and nephroblastoma in children and its value in assessing disease prognosis[J]. CJCP, 2023, 25(5): 483-488.
Verma N, Kumar A. Clinicoepidemiological profile and outcome of children with Wilms tumor in a developing country[J]. J Pediatr Hematol Oncol, 2016, 38(7): e213-e216. PMID: 27299590. DOI: 10.1097/MPH.0000000000000603.
3 Onuigbo WIB. Comparative approach to the epidemiology of Wilm's tumor[J]. Arch Cancer Res, 2016, 4(1): 48. DOI: 10.21767/2254-6081.100048.
7 Bersanelli M, Vaglio A, Sverzellati N, et al. Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors[J]. J Clin Oncol, 2017, 35(7_suppl): 50. DOI: 10.1200/JCO.2017.35.7_suppl.50.
Grant WB. Vitamin D status may explain racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era[J]. Cancer, 2016, 122(24): 3892-3893. PMID: 27627191. DOI: 10.1002/cncr.30344.
Rose TL, Milowsky MI. Reply to vitamin D status may explain racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era[J]. Cancer, 2016, 122(24): 3893. PMID: 27627047. DOI: 10.1002/cncr.30343.
Darling AL, Abar L, Norat T. WCRF-AICR continuous update project: systematic literature review of prospective studies on circulating 25-hydroxyvitamin D and kidney cancer risk[J]. J Steroid Biochem Mol Biol, 2016, 164: 85-89. PMID: 26454157. DOI: 10.1016/j.jsbmb.2015.10.001.
Lin G, Ning L, Gu D, et al. Examining the association of circulating 25-hydroxyvitamin D with kidney cancer risk: a meta-analysis[J]. Int J Clin Exp Med, 2015, 8(11): 20499-20507. PMID: 26884966. PMCID: PMC4723811.
Grant WB. Differences in 25-hydroxyvitamin D concentrations may explain the black-white differences in chronic kidney disease and risk of renal cell carcinoma[J]. Epidemiology, 2015, 26(4): e48-e49. PMID: 25899998. DOI: 10.1097/EDE.0000000000000309.
17 Joh HK, Giovannucci EL, Bertrand KA, et al. Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer[J]. FASEB J, 2013, 27(S1): 622.15. DOI: 10.1096/fasebj.27.1_supplement.622.15.
Helzlsouer KJ, Gallicchio L. Shedding light on serum vitamin D concentrations and the risk of rarer cancers[J]. Anticancer Agents Med Chem, 2013, 13(1): 65-69. PMID: 23094922. DOI: 10.2174/1871520611307010065.
Nagakura K, Nakamura H, Hayakawa M, et al. An inhibitory effect of 1 alpha, 25-dihydroxyvitamin D3 on the growth of the receptor-containing human renal carcinoma cell lines[J]. Nihon Hinyokika Gakkai Zasshi, 1985, 76(12): 1901-1908. PMID: 3012170. DOI: 10.5980/jpnjurol1928.76.12_1901.
Dormoy V, Béraud C, Lindner V, et al. Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma[J]. Carcinogenesis, 2012, 33(11): 2084-2093. PMID: 22843547. DOI: 10.1093/carcin/bgs255.
Lambert JR, Eddy VJ, Young CD, et al. A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth[J]. Cancer Prev Res (Phila), 2010, 3(12): 1596-1607. PMID: 21149334. PMCID: PMC3059596. DOI: 10.1158/1940-6207.CAPR-10-0122.
